The therapeutic landscape for menin inhibitors has undergone a remarkable transformation, evolving from theoretical research concepts into a dynamic class of targeted oncology agents with substantial clinical promise. As researchers advance their comprehension of menin's pivotal function in epigenetic mechanisms and cancer biology, pharmaceutical enterprises are increasingly focused on...